Stock Track | Humacyte Shares Plunge as Q3 Earnings Miss Estimates

Stock Track11-08

Shares of Humacyte, Inc. (NASDAQ: HUMA) plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The biotechnology firm missed analyst expectations on both revenue and earnings for the quarter ended September 30, 2024.

Humacyte reported a Q3 GAAP net loss of $39.2 million, or $0.33 per share, significantly wider than the consensus estimate of $30 million loss. The company's revenue for the quarter also fell short, with operating expenses totaling $30.233 million compared to the expected $29.7 million.

The lackluster financial performance has raised concerns among investors about the company's ability to achieve profitability in the near future. Humacyte's management will likely provide further insights and guidance during the upcoming earnings call.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141044848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141044848","market":"hk","top_or_hot":-1,"title":"Stock Track | Humacyte Shares Plunge as Q3 Earnings Miss Estimates","media":"Stock Track","content":"<p>Shares of Humacyte, Inc. (NASDAQ: HUMA) plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The biotechnology firm missed analyst expectations on both revenue and earnings for the quarter ended September 30, 2024.</p>\n\n<p>Humacyte reported a Q3 GAAP net loss of $39.2 million, or $0.33 per share, significantly wider than the consensus estimate of $30 million loss. The company's revenue for the quarter also fell short, with operating expenses totaling $30.233 million compared to the expected $29.7 million.</p>\n\n<p>The lackluster financial performance has raised concerns among investors about the company's ability to achieve profitability in the near future. Humacyte's management will likely provide further insights and guidance during the upcoming earnings call.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Humacyte Shares Plunge as Q3 Earnings Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Humacyte Shares Plunge as Q3 Earnings Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 21:14 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Humacyte, Inc. (NASDAQ: HUMA) plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUMA","symbol_name":"Humacyte, Inc.","start_time":0,"source_url":"","article_id":"1141044848","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141044848","pubTimestamp":1731071664,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Humacyte, Inc.  plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The biotechnology firm missed analyst expectations on both revenue and earnings for the quarter ended September 30, 2024.Humacyte reported a Q3 GAAP net loss of $39.2 million, or $0.33 per share, significantly wider than the consensus estimate of $30 million loss. The company's revenue for the quarter also fell short, with opera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUMA":"Humacyte, Inc."},"translate_title":"股票追踪Humacyte股价暴跌，第三季度盈利未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1},"content_text":"Shares of Humacyte, Inc. (NASDAQ: HUMA) plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The biotechnology firm missed analyst expectations on both revenue and earnings for the quarter ended September 30, 2024.\nHumacyte reported a Q3 GAAP net loss of $39.2 million, or $0.33 per share, significantly wider than the consensus estimate of $30 million loss. The company's revenue for the quarter also fell short, with operating expenses totaling $30.233 million compared to the expected $29.7 million.\nThe lackluster financial performance has raised concerns among investors about the company's ability to achieve profitability in the near future. Humacyte's management will likely provide further insights and guidance during the upcoming earnings call.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141044848"}